Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors

References

• Kwon YH, Fingert JH, Kuehn MH, et al. Primary open-angle glaucoma. N Engl J Med. 2009;360(11):1113–1124.
   PubMed Web of Science ®Google Scholar
• Mantravadi AV, Vadhar N. Glaucoma. Prim Care Clin Office Pract. 2015;42:437–449.
   PubMed Web of Science ®Google Scholar
• Kingman S. Glaucoma is second leading cause of blindness globally. Bulletin of the World Health Organisation. 2004;82(11):887–888.
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
   PubMed Web of Science ®Google Scholar
• Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. Baltimore eye survey. JAMA. 1991;266:369–374.
   PubMed Web of Science ®Google Scholar
• The Eye Disease Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532–538.
   PubMedGoogle Scholar
• Hillman J. Acute closed-angle glaucoma: an investigation into the effect of delay in treatment. Br J Ophthalmol. 1979;63:817–821.
   PubMed Web of Science ®Google Scholar
• Foster PJ, Buhrmann R, Quigley HA, et al. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002 Feb;86(2):238–242.
   PubMed Web of Science ®Google Scholar
• Hatt S, Wormald R, Burr J. Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database Syst Rev. 2006;18(4):CD006129.
   Google Scholar
• Mills RP. Glaucoma screening: the value is in the details. Am J Ophthalmol. 2008;145(1):3–4.
   PubMed Web of Science ®Google Scholar
• Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol. 1983;118:166–191.
   PubMed Web of Science ®Google Scholar
• Anderson DR. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14:86–90.
   PubMedGoogle Scholar
• Gordon MO, Kass MA. The ocular hypertension treatment study: design and baseline description of the participants. Arch Ophthalmol. 1999;117:573–583.
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, et al. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106:2144–2153.
   PubMed Web of Science ®Google Scholar
• Musch DC, Lichter PR, Guire KE, et al. The collaborative initial glaucoma treatment study: study design, methods, and baseline characteristics of enrolled pa- tients. Ophthalmology. 1999;106:653–662.
   PubMed Web of Science ®Google Scholar
• Ederer F, Gaasterland DE, Sullivan EK, et al. The advanced glaucoma intervention study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials. 1994;15:299–325.
   PubMedGoogle Scholar
• Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2013;28(2):CD006539.
   Google Scholar
• Johnson TV, Bull ND, Hunt DP, et al. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci. 2010;51(4):2051–2059.
   PubMed Web of Science ®Google Scholar
• Johnson TV, Bull ND, Martin KR. Neurotrophic factor delivery as a protective treatment for glaucoma. Exp Eye Res. 2011;93(2):196–203.
   Google Scholar
• Goel M, Picciani RG, Lee RK, et al. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4:52–59.
   PubMedGoogle Scholar
• Lin J-C. The use of ocular hypotensive drugs for glaucoma treatment: changing trend in Taiwan from 1997 to 2007. J Glaucoma. 2015;24(5):364–371.
   PubMed Web of Science ®Google Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126(3):400–408.
   PubMed Web of Science ®Google Scholar
• Singh K, Shrivastava A. Medical management of glaucoma: principles and practice. Indian J Ophthalmol. 2011;59(suppl1):S88–S92.
   PubMed Web of Science ®Google Scholar
• Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014;5(1):30–43.
   PubMedGoogle Scholar
• Stein JD, Ayyagari P, Sloan FA, et al. Rates of glaucoma medication utilization among persons with primary open-angle glaucoma 1992 to 2002. Ophthalmology. 2008;115:1315–1319.
   PubMed Web of Science ®Google Scholar
• Winkler N, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30(2–3):102–109.
   PubMed Web of Science ®Google Scholar
• Ota T, Aihara M, Saeki T, et al. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Oph- thalmol Vis Sci. 2006;47:3395–3399.
   PubMed Web of Science ®Google Scholar
• Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 2000;11:112–115.
   PubMedGoogle Scholar
• Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske C, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268–1279.
   PubMed Web of Science ®Google Scholar
• McKinnon SJ, Goldberg LD, Peeples P, et al. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008;14(1 Suppl):S20–7.
   PubMedGoogle Scholar
• Gieser DK, Tracy WR, O’Connell W, et al. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study. J Glaucoma. 2006;15:419–425.
   PubMed Web of Science ®Google Scholar
• Rolim De Moura C, Paranhos A, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev. 2007 Oct 17;4:CD003919.
   PubMed Web of Science ®Google Scholar
• Lamoureux EL, Mcintosh R, Constantinou M, et al. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials. 2015;16:406.
   PubMed Web of Science ®Google Scholar
• Waterman H, Evans JR, Gray TA, et al. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev. 2013;4:CD006132.
   PubMed Web of Science ®Google Scholar
• Kosoko O, Quigley HA, Vitale S, et al. Risk factors for noncompliance with glaucoma follow-up visits in a residents’ eye clinic. Ophthalmology. 1998;105:2105–2111.
   PubMed Web of Science ®Google Scholar
• Katz J, Gilbert D, Quigley HA, et al. Estimating progression of visual field loss in glaucoma. Ophthalmology. 1997;104:1017–1025.
   PubMed Web of Science ®Google Scholar
• Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Topouzis F, Leliopoulou O, et al. 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology. 2006;113(5):761.e1–765.e1.
   Web of Science ®Google Scholar
• Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53:S93–105.
   PubMed Web of Science ®Google Scholar
• Zhang WY, Po AL, Dua HS, et al. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2001;85:983–990.
   PubMed Web of Science ®Google Scholar
• Fraser SG. Wormald RP: hospital episode statistics and changing trends in glaucoma surgery. Eye. 2008;22:3–7.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–423.
   PubMed Web of Science ®Google Scholar
• Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008;53(suppl 1):S69–84.
   Google Scholar
• Henry JC, Peace JH, Stewart JA, et al. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2(3):613–621.
   PubMedGoogle Scholar
• Day DG, Walters TR, Schwartz GF, et al. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol. 2013;97:989–993.
   PubMed Web of Science ®Google Scholar
• Sanford M. Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension. Clin Drug Investig. 2014;34(7):521–528.
   PubMed Web of Science ®Google Scholar
• Inoue K, Soeda S, Tomita G. Comparison of latanoprost/timolol with carbonic anhydrase inhibitor and dorzolamide/timolol with prostaglandin analog in the treatment of glaucoma. J Ophthalmol. 2014;2014:975429.
   PubMedGoogle Scholar
• Smid SD. Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides. Clin Ophthalmol. 2009;3:663–670.
   PubMedGoogle Scholar
• Cantor LB. Clinical pharmacology of bimatoprost. Expert Opin Drug Metab Toxicol. 2005;1:151–157.
   PubMedGoogle Scholar
• Burk RM, Woodward DF. A historical perspective and recent advances in prostamide research and therapeutics. Curr Opin Drug Discov Devel. 2007;10:413–421.
   PubMedGoogle Scholar
• Camras CB, Sharif N, Wax M, et al. Bimatoprost, the prodrug of a prostaglandin analogue. Br J Ophthalmol. 2008;92:862–863.
   PubMed Web of Science ®Google Scholar
• Bahler CK, Howell KG, Hann CR, et al. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol. 2008;145:114–119.
   PubMed Web of Science ®Google Scholar
• Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Investig Ophthal Vis Sci. 2007;48:4107–4115.
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17:667–673.
   PubMed Web of Science ®Google Scholar
• Paletta Guedes RA, Paletta Guedes VM, Freitas SM, et al. Quality of life of glaucoma patients under medical therapy with different prostaglandins. Clin Ophthalmol. 2012;6:1749–1753.
   PubMedGoogle Scholar
• Goldberg I, Clement CI, Chiang TH, et al. Assessing quality of life in patients with glaucoma using the glaucoma quality of life-15 (GQL-15) questionnaire. J Glaucoma. 2009;18:6–12.
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1–9.e2.
   PubMed Web of Science ®Google Scholar
• Fechtner R. Prevalence of ocular surface disease symptoms in glaucoma patients on IOP-lowering medications. Pre- sented at: American Glaucoma Society 2008 annual meeting, 3-6-0008. 2008 March 6–9, Washington, DC.
   Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–355.
   PubMed Web of Science ®Google Scholar
• Kahook MY, Ammar DA. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells. J Ocul Pharmacol Ther. 2010;26(3):259–263.
   PubMed Web of Science ®Google Scholar
• Honrubia F, Garcia-Sanchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials. Br J Ophthalmol. 2009;93:316–321.
   PubMed Web of Science ®Google Scholar
• Lee AJ, McCluskey P, Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010;4:741–764.
   PubMedGoogle Scholar
• Parrish RK, Palmberg P, Sheu W-P. The XLT study group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688–703.
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Hahn SR, Gelb L, et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Oc Pharm Ther. 2009;25(2):145–152.
   PubMed Web of Science ®Google Scholar
• Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122(7):957–965.
   PubMedGoogle Scholar
• Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472–484.
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Sugahara M, et al. Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension. Clin Ophthalmol. 2012;6:111–116.
   PubMedGoogle Scholar
• Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124(4):544–547.
   PubMed Web of Science ®Google Scholar
• Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(Suppl 10):S185–S202.
   PubMed Web of Science ®Google Scholar
• Skuta GL. Should beta-blockers be abandoned as initial monotherapy in chronic open angle glaucoma? View 2. Br J Ophthalmol. 2002;86(6):693–694.
   PubMed Web of Science ®Google Scholar
• Shaikh MY, Bodla AA. Letter to the editor: hypertrichosis of the eyelashes from prostaglandin analog use: a blessing or a bother to the patient? J Ocul Pharmacol Ther. 2006;22(1):76–77.
   PubMed Web of Science ®Google Scholar
• Sakata R, Shirato S, Miyata K, et al. Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution. Eye. 2014;28:1446–1451.
   PubMed Web of Science ®Google Scholar
• Herndon LW, Williams RD, Wand M, et al. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol. 2003;135(5):713–715.
   PubMed Web of Science ®Google Scholar
• Wand M, Ritch R, Isbey EK, et al. Latanoprost and periocular skin changes. Arch Ophthalmol. 2001;119(4):614–615.
   PubMedGoogle Scholar
• Doshi M, Edward DP, Osmanovic S. Clinical course of bimatoprost- induced periocular skin changes in Caucasians. Ophthalmology. 2006;113(11):1961–1967.
   PubMed Web of Science ®Google Scholar
• Warwar RE, Bullock JD, Ballal D. Cystoid macular oedema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105(2):263–268.
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Kostakou A, Halkiadakis I, et al. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):775–780.
   PubMed Web of Science ®Google Scholar
• Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular oedema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998;126(4):602–604.
   PubMed Web of Science ®Google Scholar
• Krohn J, Hove VK. Iris cyst associated with topical administration of latanoprost. Am J Ophthalmol. 1999;127(1):91–93.
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides. Curr Med Res Opin. 2007;23(3):595–599.
   PubMed Web of Science ®Google Scholar
• Noecker RS, Dirks MS, Choplin NT, et al. for the Bimatoprost/ latanoprost study group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63.
   PubMed Web of Science ®Google Scholar
• DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(Suppl 4):S353–S360.
   PubMed Web of Science ®Google Scholar
• Gandolfi S, Simmons S, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension.. Adv Ther. 2001;18:110–121.
   PubMed Web of Science ®Google Scholar
• Friedman DS, West SK, Muñoz B, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532–538.
   PubMedGoogle Scholar
• Varma R, Lee PP, Goldberg I, et al. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152(4):515–522.
   PubMed Web of Science ®Google Scholar
• Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754–1760.
   PubMedGoogle Scholar
• Mitchell P, Smith W, Attebo K, et al. Prevalence of open-angle glaucoma in Australia. Blue mountains eye study. Ophthalmol. 1996;103(1):1661–1669.
   PubMed Web of Science ®Google Scholar
• Orme M, Collins S, Loftus J. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the uk: optimizing cost-effectiveness and clinic resources by minimizing therapy switches. J Glacuoma. 2012;21(7):433–449.
   PubMed Web of Science ®Google Scholar
• De Natale R, Le Pen C, Berdeaux G. Efficiency of glaucoma drug regulation in 5 European countries: a 1995-2006 longitudinal prescription analysis. J Glaucoma. 2011;20(4):234–239.
   PubMed Web of Science ®Google Scholar
• Owen CG, Carey IM, De Wilde S, et al. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. Br J Ophthalmol. 2006;90:861–868.
   PubMed Web of Science ®Google Scholar
• Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005;22(1):1–21.
   PubMed Web of Science ®Google Scholar
• Connor AJ, Fraser SG. Glaucoma prescribing trends in England 2000 to 2012. Eye. 2014;28:863–869.
   PubMed Web of Science ®Google Scholar
• Schmier JK, Lau EC, Covert DW. Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. Clin Ophthalmol. 2010;4:1137–1143.
   PubMedGoogle Scholar
• Chan HH, Wong TT, Lamoureux E, et al. A survey on the preference of sustained glaucoma drug delivery systems by Singaporean Chinese patients: a comparison between subconjunctival, intracameral, and punctal plug routes. J Glaucoma. 2015;24(7):485–492.
   PubMed Web of Science ®Google Scholar
• Crowston JG, Lindsey JD, Aihara M, et al. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest Ophthalmol Vis Sci. 2004;45(10):3555–3559.
   PubMed Web of Science ®Google Scholar
• Crowston JG, Lindsey JD, Morris CA, et al. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Opthalmol Visual Sci. 2005;46(12):4571–4577.
   PubMed Web of Science ®Google Scholar
• Imai K, Ueta M, Mori K, et al. Expression of prostaglandin F receptor in scleral and subconjunctival tissue. Br J Ophthalmol. 2012;96:1148–1149.
   PubMed Web of Science ®Google Scholar
• Anthony TL, Lindsey JD, Aihara M, et al. Detection of prostaglandin EP(1), EP (2), and FP receptor subtypes in human sclera. Invest Ophthalmol Vis Sci. 2001;42(13):3182–3186.
   PubMed Web of Science ®Google Scholar
• Schlotzer-Schrehardt U, Zenkel M, Nüsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43(5):1475–1487.
   PubMed Web of Science ®Google Scholar
• Garcia-Lopez A, Paczka JA, Jimenez-Roman J, et al. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. BMC Ophthalmol. 2014;14:161–172.
   PubMed Web of Science ®Google Scholar
• Hofman A, Grobbee DE, De Jong PTVM, et al. Determinants of disease and disability in the elderly: the Rotterdam elderly study. Eur J Epidemiol. 1991 Jul;7(4):403–422.
   Web of Science ®Google Scholar
• Yamane S, Karakawa T, Nakayama S, et al. IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547–2552.
   PubMed Web of Science ®Google Scholar
• Berlin MS, Rowe-Rendleman C, Ahmed I, et al. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study. Br J Ophthalmol. 2015;0:1–5.
   Google Scholar
• Baudouin C. Detrimental effect of preservatives in eye drops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716–726.
   PubMed Web of Science ®Google Scholar
• Daull P, Buggage R, Lambert G, et al. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models. J Ocul Pharmacol Ther. 2012;28(5):515–523.
   PubMed Web of Science ®Google Scholar
• Kopczynski CC, Epstein DL. Emerging trabecular outflow drugs. J Ocul Pharmacol Ther. 2014;30:85–87.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731–736.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Levy B, Ramirez N, et al. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomized, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2015;0:1–6.
   Google Scholar
• Kiel JW, Kopczynski C. Effect of AR-13324 on episcleral venous pressure in Dutch Belted rabbits. J Ocul Pharmacol Ther. 2015;31:146–151.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Agarwal P. Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways. Expert Opin Ther Targets. 2014;18(5):527–539.
   PubMed Web of Science ®Google Scholar
• Ichhpujani P, Katz LJ, Hollo G, et al. Comparison of human ocular distribution of bimatoprost and latanoprost. J Ocular Pharmacol Ther. 2012;28(2):134–146.
   PubMed Web of Science ®Google Scholar
• Natarajan JV, Ang M, Darwitan A, Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Internation J Nanomedicine. 2012;7:123–131.
   PubMed Web of Science ®Google Scholar
• Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci. 1982;22:220–227.
   PubMed Web of Science ®Google Scholar
• Wong TT, Novack GD, Natarajan JV, et al. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv And Transl Res. 2014;4:303–309.
   PubMed Web of Science ®Google Scholar
• Voss K, Falke K, Bernsdorf A, et al. Development of a novel injectable drug delivery system for subconjunctival glaucoma treatment. J Control Release. 2015;214:1–11.
   PubMed Web of Science ®Google Scholar
• Franca JR, Foureaux G, Fuscaldi LL, et al. Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation. PLoS ONE. 2014;9(4):e95461.
   PubMed Web of Science ®Google Scholar
• Zambito Y, Di Colo G. Chitosan and its derivatives as intraocular penetration enhancers. J Drug Deliv Sci Technol. 2010;20:45–52.
   Web of Science ®Google Scholar
• Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441–463.
   PubMed Web of Science ®Google Scholar
• DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes. Med Care. 2002;40(9):794–811.
   PubMed Web of Science ®Google Scholar
• Hermann MM, Papaconstantinou D, Muether PS, et al. Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring. Acta Ophthalmol. 2011;89(4):e300–e305.
   PubMed Web of Science ®Google Scholar
• Chong RS, Su DHW, Tsai A, et al. Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma. J Glaucoma. 2013;22:190–194.
   PubMed Web of Science ®Google Scholar
• Foo RCM, Lamoureux EL, Wong RCK, et al. Acceptance, attitudes, and beliefs of singaporean chinese toward an ocular implant for glaucoma drug delivery. Invest Ophthalmol Vis Sci. 2012;53:8240–8245.
   PubMed Web of Science ®Google Scholar
• Brissette AR, Mednick ZD, Schweitzer KD, et al. Punctal plug retention rates for the treatment of moderate to severe dry eye: a randomized, double-masked, controlled clinical trial. Am J Ophthalmol. 2015;160(2):238–242.
   PubMed Web of Science ®Google Scholar
• Kaido M, Ishida R, Dogru M, et al. Comparison of retention rates and complications of 2 different types of silicon lacrimal punctal plugs in the treatment of dry eye disease. Am J Ophthalmol. 2013;155(4):648–653.
   PubMed Web of Science ®Google Scholar
• Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol. 2001;131(1):30–36.
   PubMed Web of Science ®Google Scholar
• Hamano T. Lacrimal duct occlusion for the treatment of dry eye. Semin Ophthalmol. 2005;20(2):71–74.
   PubMedGoogle Scholar
• Altan-Y R, Genoglu EA, Akova YA, et al. Silicone versus collagen plugs for treating dry eye: results of a prospective randomized trial including lacrimal scintigraphy. Am J Ophthamol. 2005;140(1):88–93.
   PubMed Web of Science ®Google Scholar
• Hirai K, Takano Y, Uchio E, et al. Clinical evaluation of the therapeutic effects of atelocollagen absorbable punctal plugs. Clin Ophthalmol. 2012;6:133–138.
   PubMedGoogle Scholar